Market Place
Sourcing Support
U.S. Government Awards BioCryst $69 Million RAPIVAB Contract
30 Sep 2024 //
GLOBENEWSWIRE
NV-387 Broad-Spectrum Antiviral Could Combat Bird Flu H5N1, Says NanoViricides
24 Jun 2024 //
ACCESSWIRE
U.S. Government Exercises Option to Purchase Additional RAPIVAB from BioCryst
25 Aug 2022 //
GLOBENEWSWIRE
U.S. Government Exercises Option to Purchase Additional RAPIVAB from BioCryst
01 Sep 2021 //
GLOBENEWSWIRE
BioCryst Announces FDA Approval of Supplemental NDAfor RAPIVAB®
03 Feb 2021 //
BIOSPACE
BioCryst wins approval HAE pill charges half-a-M dollars, will anyone take it?
07 Dec 2020 //
ENDPTS
BioCryst Announces Full Exercise of Underwriters’ Option
18 Nov 2019 //
BIOSPACE
BioCryst Announces APeX-1 Clinical Trial Results for BCX7353 Published in NEJM
30 Jul 2018 //
GLOBENEWSWIRE
Biocryst UK `s Alpivab (Peramivir) Receives Approval In Europe
26 Apr 2018 //
EMA
Five new medicines backed for EU approval
26 Feb 2018 //
PHARMA TIMES
EMA’s CHMP Recommends Five New Medicines for Approval
26 Feb 2018 //
RAPS
Five medicines recommended for approval, including two orphans
23 Feb 2018 //
EMA
BioCryst Announces RAPIVAB® (peramivir injection) & Galidesivir
04 Oct 2017 //
GLOBENEWSWIRE
BioCryst’s RAPIVAB peramivir Inj Receives FDA Approval for Pediatric Indication
21 Sep 2017 //
GLOBENEWSWIRE
Australia`s CSL`s rIX-FP PhIII meets endpoint, firm buys Rapivab rights from BioCryst
29 Jun 2015 //
FIERCE PHARMA ASIA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.